Valeant raises offer to acquire Salix
LAVAL, Quebec, and RALEIGH, N.C. — Valeant Pharmaceuticals International Inc. has hiked its offer to buy Salix Pharmaceuticals, Ltd. under an amended agreement. The companies said Monday that Valeant boosted its cash offer to acquire all the outstanding common stock of Salix to $173 per share, or a total deal of about $15.8 billion, from $158
